Hythiam CEO Terren Peizer to Speak at National Association of Addiction Treatment Providers' CEO Summit in Los Angeles; Peizer Will Discuss 'Addiction's Physiological Frontiers'.

LOS ANGELES -- Hythiam, Inc. (NASDAQ:HYTM), a healthcare services management company that licenses the PROMETA(TM) physiological protocols designed to treat substance dependence, announced today that Terren S. Peizer, Hythiam's Chairman and CEO will be speaking at the National Association of Addiction Treatment Providers' (NAATP) CEO Summit in Los Angeles, Jan. 19, 2006, at 6pm PST. The invitation only event is being held at The Fairmont Miramar Hotel in Santa Monica.

The NAATP CEO Summits, sponsored by the Van Wagner Insurance Group, Treatment Magazine and National Association of Addiction Treatment Providers, are a series of one-evening summits held regionally across the nation and given for the benefit of the addiction treatment industry leadership. Mr. Peizer is the fourth among a prominent group of industry leaders who have spoken at the NAATP CEO Summits, including CRC Health Group CEO Barry Karlin in South Florida, Hazelden CEO Ellen Breyer in Chicago, and Caron Foundation CEO Doug Tieman in New York.

Mr. Peizer will be addressing an assembled group of West Coast addiction treatment CEOs on the subject of "Addiction's Physiological Frontier," a topic Mr. Peizer is familiar with since Hythiam is in the process of delivering to the treatment industry innovative, physiological solutions to complement existing behavioral and psychosocial treatment modalities.

About NAATP

For more than twenty-five years since its founding in 1978, the National Association of Addiction Treatment Providers (NAATP), which represents nearly 275 not-for-profit and for-profit providers (freestanding and hospital-based programs, which offer a full continuum of care from outpatient, partial hospitalization and inpatient rehabilitation regimes), has acted as the voice of private alcoholism and drug dependency treatment programs throughout the U.S. That voice has been heard time and time again -- in Congress, in the insurance industry, in the utilization review arena and in the chemical dependency treatment field itself.

About PROMETA(TM)

Hythiam's PROMETA(TM) treatment protocols are designed for use by healthcare providers seeking to treat individuals diagnosed with dependencies to alcohol, cocaine or methamphetamines, as well as combinations of these drugs. The PROMETA(TM) protocols include medically supervised procedures designed to address both the neurochemical imbalances in the brain and some of the nutritional deficits caused or worsened by substance dependence. Changes in brain chemistry and function play an important role in the physical and behavioral symptoms of substance dependence, including tolerance, withdrawal symptoms, craving and relapse. The PROMETA(TM) protocols also provide for one month of prescription medication and nutritional supplements, combined with psychosocial or other recovery-oriented therapy chosen by the patient in conjunction with their treatment provider. As a result, PROMETA(TM) represents an innovative approach to managing alcohol, cocaine or methamphetamine dependence that is designed to address physiological, nutritional and psychosocial aspects of the disease, and is thereby intended to offer patients an opportunity to achieve sustained recovery.

About Hythiam, Inc.

Hythiam(R) is a healthcare services management company, focused on delivering solutions for those suffering from alcoholism and other substance dependencies. Hythiam researches, develops, licenses and commercializes innovative physiological treatment protocols that seek to address substance dependence. Additionally, Hythiam provides proprietary administrative services to assist physicians and facilities with staff education, marketing and sales support, and outcomes tracking for data analysis. For further information, please visit www.hythiam.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and lack of statistically significant formal research studies, the risk that treatment protocols might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the healthcare industry; and additional risks factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov.